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Purpose: To explore the visual acuity and anatomic outcomes over 24 months of patients with diabetic
macular edema (DME) who showed a delayed anatomic response after 3 ranibizumab injections in the RIDE and
RISE trials.
Design: Analysis of data from RIDE and RISE, 2 phase III, parallel, randomized, multicenter, double-masked
trials (ClinicalTrials.gov identiﬁers, NCT00473382 and NCT00473330).
Participants: Patients with DME (n ¼ 681) who received monthly intravitreal ranibizumab 0.3-mg injections,
ranibizumab 0.5-mg injections, or sham injections.
Methods: Patients were separated into 3 groups: delayed responders (ranibizumab-treated patients with
10% central foveal thickness [CFT] reduction after 3 injections), immediate responders (ranibizumab-treated
patients with >10% CFT reduction after 3 injections), and sham recipients. Central foveal thickness was
measured by time-domain optical coherence tomography, best-corrected visual acuity (BCVA) was measured by
Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores, and diabetic retinopathy (DR) was measured
by the standardized ETDRS severity scale (using fundus photographs).
Main Outcome Measures: Month-24 CFT, BCVA, and DR severity levels.
Results: In RIDE and RISE, 9% to 10% of ranibizumab-treated eyes were delayed responders. At month 24,
delayed responders had less CFT reduction (median, 102 mm) from baseline compared with immediate
responders (median, 274 mm; P < 0.0001). Delayed responders gained a median of 10 letters at 24 months,
similar to immediate responders (14 letters; P ¼ 0.15). At month 24, DR improvement among the delayed re-
sponders (31% and 22% of patients with 2- or 3-step DR improvement, respectively) was comparable with
that among immediate responders (42% and 17%, respectively; P ¼ 0.21 and P ¼ 0.48, respectively).
Conclusions: With continued treatment, at month 24, patients with DME with delayed anatomic response
(10% CFT reduction) after 3 ranibizumab injections had visual acuity gains and DR improvement similar to those
of patients with DME who had immediate anatomic response. Ophthalmology 2016;123:1345-1350 ª 2016 by the
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The treatment paradigm for diabetic macular edema (DME)
has changed dramatically in recent years.1e3 With the
various treatment options, clinicians must determine when a
patient has failed one treatment and when to switch to
another. A retrospective claims analysis (2008e2011) of
patients newly diagnosed with retinal vein occlusion or
DME revealed that patients with DME received an average
of 2.2 to 3.6 bevacizumab injections annually,4 markedly
fewer than the number received by patients in major
clinical trials of ranibizumab. These ﬁndings suggest that
antievascular endothelial growth factor (VEGF) therapy is
underused in the treatment of DME and also raise the
question of when to designate a patient as nonresponsive
to anti-VEGF treatment.
The RIDE and RISE trials (ClinicalTrials.gov identiﬁers,
NCT00473382 and NCT00473330) were 2 phase III, par-
allel, randomized, multicenter, double-masked trials in 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.which patients with DME received monthly intravitreal
ranibizumab 0.3-mg injections, ranibizumab 0.5-mg
injections, or sham injections. These studies were sham
controlled for the ﬁrst 2 years; in the third year, patients in
the sham group could cross over to receive ranibizumab
0.5 mg monthly. Visual acuity and anatomic improvements
generally were seen in ranibizumab-treated patients as early
as 7 days after the ﬁrst injection and were maintained over 3
years.5,6
The objective of this analysis was to answer the
following clinical questions: When is it appropriate to say
that a patient has failed to respond to anti-VEGF treatment?
If a patient does not respond initially, does that mean they
will never respond? Our study explored the visual acuity,
optical coherence tomography (OCT), and diabetic reti-
nopathy (DR) outcomes over 24 months in patients with
DME (n ¼ 681) who had little or no immediate anatomic1345http://dx.doi.org/10.1016/j.ophtha.2016.02.007
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Figure 1. Bar graphs showing baseline values of (A) median central foveal
thickness (CFT) and (B) median best-corrected visual acuity (BCVA)
among the ranibizumab (RBZ)-treated delayed responders (10% CFT
reduction after 3 injections), RBZ-treated immediate responders (>10%
CFT reduction after 3 injections), and sham-treated patients. Data are from
time-domain optical coherence tomography images and include patients
treated with RBZ 0.3 or 0.5 mg. Error bars are lower and upper quartiles.
The Wilcoxon rank-sum test was used to compare between responder
groups. ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Ophthalmology Volume 123, Number 6, June 2016response after 3 ranibizumab injections in the phase III
RIDE and RISE trials.
Methods
The methods of RIDE and RISE have been described previously in
detail.5,6 These trials complied with the Health Insurance Porta-
bility and Accountability Act and the Declaration of Helsinki.
Protocols were approved by institutional review boards or ethics
committees, and written informed consent was obtained from all
patients before study entry.
This analysis was limited to data at month 24, before the sham
recipients crossed over to ranibizumab. All patients were separated
into 3 responder status groups based on their treatment arm and
central foveal thickness (CFT) change from baseline after 3 in-
jections of ranibizumab: delayed responders (ranibizumab-treated
patients with 10% CFT reduction), immediate responders (rani-
bizumab-treated patients with >10% CFT reduction), and sham re-
cipients. The 3-injection cutoff was selected because after 3 doses
(which can be considered loading doses), patients were eligible for
laser treatment. Because one of the criteria for laser treatment was
CFT of 250 mm or more with a less than 50-mm reduction from the
prior month’s measurement, reliable interpretation of the data is
challenging after 3 doses because of the confounding effect of laser
treatment. Overall, 20% to 39% of ranibizumab-treated patients and
70% to 74% of sham-treated patients received macular laser treat-
ment, and 0% to 1.6% of ranibizumab-treated patients and 11% to
12% of sham-treated patients received panretinal photocoagulation
laser in the RIDE and RISE studies at 24 months.5
Methodology for measuring anatomic outcome of CFT on time-
domain OCT, best-corrected visual acuity (BCVA) according to
Early Treatment Diabetic Retinopathy Study (ETDRS) letter score,
and DR by the standardized ETDRS severity scale (using fundus
photographs) was the same as described previously.5 Analyses
were based on observed data without imputation for missing
values. Descriptive summaries by responder status were
generated at baseline and month 24. Data were analyzed by
medians and interquartile ranges because of the small sample
sizes of delayed responders. The Kaplan-Meier survival method
was used to estimate the median time to ﬁrst anatomic response
(>10% CFT reduction). The Wilcoxon rank-sum test was used to
compare between the responder groups the distribution of contin-
uous CFT, BCVA, and DR end points at baseline and month 24.
The proportions of patients with CFT of 250 mm or less at baseline
and month 24, 10-letter or more loss at month 24, and 2- or 3-step
DR improvement at month 24 were compared between responder
groups using the Fisher exact test.
Results
Overall, in the RIDE and RISE trials, the median time to ﬁrst
anatomic response was 9 days for ranibizumab-treated patients.
After 3 injections, 10% (23/224) of the ranibizumab 0.3-mg group
and 9% (21/229) of the ranibizumab 0.5-mg group were delayed
responders (10% CFT reduction). The delayed responder group
was compared with the entire sham group (n ¼ 228).
Baseline Characteristics
At baseline, delayed responders had thinner retinas (median, 397 mm)
compared with immediate responders (median, 459 mm; P ¼ 0.002)
and with sham recipients (median, 460 mm; P ¼ 0.01; Fig 1A).
Overall, less than 10% of patients had CFT of 250 mm or less at
baseline: 9.1% (4/44) of delayed responders, 4.0% (16/405) of
immediate responders, and 6.4% (14/220) of sham recipients.1346Numerically, a greater proportion of delayed responders had CFT
of 250 mm or less at baseline, compared with immediate
responders and sham recipients, but the difference was not
statistically signiﬁcant (P ¼ 0.12 and P ¼ 0.51, respectively).
At baseline, delayed responders had BCVA comparable to that
of immediate responders and sham recipients (median, 63, 58, and
58 ETDRS letters, respectively; Snellen equivalent, approximately
20/62.5, approximately 20/80, and approximately 20/80, respec-
tively; P ¼ 0.19 vs. immediate responders; P ¼ 0.36 vs. sham
recipients; Fig 1B).
At baseline, there were no statistically signiﬁcant differences in
DR severity level between immediate responders and delayed re-
sponders overall (P ¼ 0.16; Table 1). However, a greater
proportion of delayed responders had only mild or moderate
nonproliferative DR (22.7% and 22.7%, respectively) at baseline,
compared with immediate responders (13.9% and 11.8%,
respectively) and sham recipients (15.1% and 13.7%, respectively).
Table 1. Diabetic Retinopathy Severity Levels at Baseline
DR Severity Level Delayed Responders (n [ 44) Immediate Responders (n [ 397) Sham (n [ 219)
10, 12 (DR absent) 0 (0) 2 (0.5) 1 (0.5)
14Ae14C, 14Z, 15, 20 (DR questionable) 1 (2.3) 3 (0.8) 3 (1.4)
35Ae35F (mild NPDR) 10 (22.7) 55 (13.9) 33 (15.1)
43Ae43B (moderate NPDR) 10 (22.7) 47 (11.8) 30 (13.7)
47Ae47D (moderately severe NPDR) 6 (13.6) 120 (30.2) 61 (27.9)
53Ae53E (severe NPDR) 2 (4.6) 19 (4.8) 11 (5.0)
60, 61A, 61B (mild PDR) 14 (31.8) 114 (28.7) 54 (24.7)
65Ae65C (moderate PDR) 1 (2.3) 12 (3.0) 11 (5.0)
71Ae71D (high-risk PDR) 0 (0) 4 (1.0) 2 (0.9)
75 (high-risk PDR) 0 (0) 1 (0.3) 0 (0)
Missing/cannot grade 0 (0) 20 (5.0) 13 (5.9)
DR ¼ diabetic retinopathy; NPDR ¼ nonproliferative diabetic retinopathy; PDR ¼ proliferative diabetic retinopathy.
Data are no. (%). The Wilcoxon rank-sum test was used to compare ranibizumab immediate responders and delayed responders (P ¼ 0.16).
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At month 24, delayed responders had less CFT reduction
(median, 102 mm) from baseline compared with immediate re-
sponders (median, 274 mm; P < 0.0001) and CFT reduction
comparable to that of sham recipients (median, 153 mm; P ¼
0.33; Fig 2A). At month 24, delayed responders had thicker retinas
compared with immediate responders (median, 209 vs. 157 mm,
respectively; P < 0.0001); median CFT was comparable between
delayed responders and sham recipients (median, 244 mm; P ¼
0.26). At month 24, a smaller proportion of delayed responders
(65.8%) had CFT of 250 mm or less compared with immediate
responders (82.8%; P ¼ 0.02); the proportion was similar to that
of the sham group (51.7%; P ¼ 0.15).
Visual Outcomes
At month 24, delayed responders and immediate responders had
comparable BCVA gain from baseline (median, 10 vs. 14 letters;
P ¼ 0.15); delayed responders had greater BCVA gain compared
with sham recipients (median, 5 letters; P ¼ 0.002; Fig 2B). Both
ranibizumab responder groups had a median BCVA of 73 ETDRS
letters (Snellen equivalent, approximately 20/40; P ¼ 0.58) at
month 24; sham recipients had a median BCVA of 65 ETDRS
letters (Snellen equivalent, approximately 20/50; P ¼ 0.001 vs.
delayed responders; Fig 2B). A similar proportion of delayed and
immediate responders gained 2 lines or more of vision (62.5%
vs. 68.0%, respectively; P ¼ 0.48) at month 24; a smaller
proportion of the sham group gained 2 lines or more (33.0%)
compared with the delayed responders (P ¼ 0.001). Comparable
ﬁndings were seen for 3-line or more gain at month 24; a similar
proportion of delayed and immediate responders gained 3 lines or
more of vision (35.0% vs. 46.8%, respectively; P ¼ 0.18), and a
smaller proportion of the sham group gained 3 lines or more
(18.9%; P ¼ 0.03 vs. delayed responders). At month 24, the pro-
portions of patients with 10-letter or more loss were low and
comparable between immediate responders (3.2%) and delayed
responders (5.0%; P ¼ 0.63). A numerically greater proportion of
sham-treated patients (13.5%) lost 10 letters or more at month 24
(P ¼ 0.18 vs. delayed responders).
Diabetic Retinopathy Outcomes
The proportions of patients with 2-step or more or 3-step or more DR
improvement at month 24 were comparable between immediate and
delayed responders (P ¼ 0.21 and P ¼ 0.48, respectively; Fig 3). A
signiﬁcantly larger proportion of delayed responders had 2-step ormore or 3-step or more DR improvement compared with the sham
group (P¼ 0.0003 andP< 0.0001, respectively) atmonth 24 (Fig 3).
Discussion
Few ranibizumab-treated eyes (9% to 10%) in RIDE and
RISE were delayed responders (10% CFT reduction after
3 injections). At 24 months, delayed responders had less
CFT reduction from baseline compared with immediate re-
sponders. Despite little or no immediate anatomic response,
signiﬁcant visual acuity improvement occurred with
continued treatment. Continuing treatment did not result in
visual loss; very few ranibizumab-treated patients (5%) lost
10 or more ETDRS letters. These delayed responders gained
a median of 10 letters at 24 months, similar to immediate
responders (14 letters). At month 24, there was also DR
improvement among the delayed responders (31% and 22%
of patients with 2- or 3-step DR improvement, respec-
tively), which was comparable with immediate responders
(42% and 17%, respectively). Our study demonstrated that
certain patients may be slow to respond anatomically, but
still can experience vision gains and DR improvement over
24 months with continued ranibizumab therapy. Our anal-
ysis focused on anatomic response because generally, in
clinical practice, decision making regarding treatment is in
large part based on OCT changes. However, our ﬁndings
reafﬁrm the discordance between retinal thickness and vi-
sual acuity.7 Many other retinal anatomic details that may
predict the potential of recovery are likely not captured in
a summary measurement such as CFT.
To further investigate potential reasons for the compar-
atively decreased anatomic improvement in the delayed re-
sponders group, we considered differences in baseline OCT.
Delayed responders had a median baseline CFT less than
400 mm, whereas immediate responders had a median
baseline CFT more than 400 mm. One hypothesis is that the
delayed responders had less of an anatomic response
compared with immediate responders because of a ﬂoor
effect; that is, patients who started with thinner CFTs did not
have excess ﬂuid to lose. However, we found that none of
the delayed responders had CFT 170 mm or less after 3
injections. In addition, in an analysis adjusting for baseline1347
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Figure 2. Graphs showing the change from baseline over 24 months in (A) median central foveal thickness (CFT) and (B) median best-corrected visual
acuity (BCVA) among the ranibizumab (RBZ)-treated delayed responders (10% CFT reduction after 3 injections), RBZ-treated immediate responders
(>10% CFT reduction after 3 injections), and sham-treated patients. Data are from time-domain optical coherence tomography images and include patients
treated with RBZ 0.3 or 0.5 mg. Error bars are lower and upper quartiles. The Wilcoxon rank-sum test was used to compare between responder groups. At
month 24, for CFT, n is 38, 338, and 176, and for BCVA, n is 40, 344, and 185, for RBZ delayed responders, RBZ immediate responders, and sham
recipients, respectively. ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Ophthalmology Volume 123, Number 6, June 2016CFT thickness, visual and anatomic results were similar to
our main analysis and were not included in this article. The
delayed responders experienced visual improvement despite
limited anatomic response; this functional response may be
the result of other positive effects of anti-VEGF therapy on
the diabetic retina besides reduction in edema. For example,
analysis of the RIDE and RISE study data demonstrated that
ranibizumab treatment improved DR severity and prevented
worsening in patients with DME.8,9 Further research is
warranted to explore the physiologic processes behind the
delayed anatomic response to anti-VEGF treatment in pa-
tients with DME.1348Studies have examined whether other baseline character-
istics affect treatment outcome with anti-VEGF therapy in
DME. For instance, other studies have found that patients
with focal DME10 or greater baseline subfoveal choroidal
thickness11 may have more potential for visual acuity
improvement. In our study, the delayed responders tended
to have signiﬁcantly thinner retinas, slightly better BCVA,
and more mild DR severity at baseline, suggesting that
these patients had more mild disease to begin with. In a
retrospective case series (n ¼ 175 eyes),12 patients with
central retinal thickness (CRT) more than 400 mm at
baseline had a greater anatomic response to bevacizumab
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Figure 3. Bar graphs showing the proportion of patients with 2-step or more or 3-step or more improvement in diabetic retinopathy (DR) at month 24. Data
include patients treated with ranibizumab (RBZ) 0.3 or 0.5 mg. The Fisher exact test was used to compare RBZ immediate responders and delayed responders
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Pieramici et al  Anatomic Response to Ranibizumab for DMEtreatment in a real-world setting; as expected, these patients
may have more room for improvement in terms of OCT
reduction. Similar to ourﬁndings, both groups (baseline CRT,
<400 and>400 mm) had signiﬁcant vision improvement, and
there was no clear difference between groups in terms of
vision gains. Likewise, in another study (n ¼ 854 eyes)
evaluating ranibizumab 0.5 mg plus prompt or deferred laser
treatment or triamcinolone 4 mg plus prompt laser treatment
for DME,13 patients with baseline central subﬁeld thickness
less than 400 mm experienced less OCT reduction than
those with baseline central subﬁeld thickness of 400 mm or
more, but there were no clinically important differences in
BCVA at 1 year between the 2 subgroups. In contrast, in the
RESTORE study (n ¼ 345) comparing laser monotherapy
with ranibizumab 0.5-mg monotherapy (3 monthly loading
doses, then as-needed injections) or combined with laser
treatment,14 patients with CRT more than 400 mm at baseline
had greater gains in BCVA from baseline compared with
those who had baseline CRT 300 to 400 mm or less than
300 mm.
It should be noted that DME is a complex disease, and as
such, there are a number of other factors that could impact
response to anti-VEGF therapy. Although generally elevated
in patients with DME compared with patients without, levels
of VEGF have been observed to be highly variable in the
vitreous of different patients.15 Furthermore, there is an
upregulation of a multitude of growth factors and cytokines
that contribute to the breakdown of the blooderetinal
barrier and consequent vascular leakage responsible for
DME, including angiopoietins, tumor necrosis factor,
interleukins, and matrix metalloproteinases.2 Therefore, it is
unsurprising that a variability in patient response to anti-
VEGF therapy has been observed in several studies. Theproportion of ranibizumab-treated DME patients gaining 3
lines or more of BCVAwas 37% to 51% in RIDE and RISE at
36 months6 and 27% to 38% in Diabetic Retinopathy
Clinical Research Network protocol I at 5 years.16
Similarly, in the VISTA and VIVID studies, 31% to 38% of
aﬂibercept-treated DME patients gained 3 lines or more of
BCVA at week 100.17 In a head-to-head comparison of aﬂi-
bercept, bevacizumab, and ranibizumab for treatment of
DME (Diabetic Retinopathy Clinical Research Network
protocol T), the proportions of patients gaining 3 lines ormore
of BCVAwere 42%, 29%, and 32%, respectively.18 As such,
it is most often the case that less than 50% of patients show 3
lines or more of visual acuity improvement in studies of anti-
VEGF therapy.
With continued treatment, delayed responders (10%
CFT reduction after 3 ranibizumab injections) had month-24
outcomes that were similar to those seen in immediate re-
sponders (>10% CFT reduction); delayed responders gained
an average of 10 letters, and up to 30% had a 2-step or more or
3-step or more improvement. Data from this analysis support
continuing ranibizumab therapy for DME even when patients
have delayed anatomic responses to treatment.
Acknowledgments. The authors thank Sherri A. Van Everen,
PharmD, for her contributions toward the development of the
concept of this study and involvement in the initial data analyses,
and Anne E. Fung, MD, for her input during the analysis of the
data.
References
1. Colucciello M. Current intravitreal pharmacologic therapies
for diabetic macular edema. Postgrad Med 2015;1–14.1349
Ophthalmology Volume 123, Number 6, June 20162. Das A, McGuire PG, Rangasamy S. Diabetic macular edema:
pathophysiology and novel therapeutic targets. Ophthalmology
2015;122:1375–94.
3. Mathew C, Yunirakasiwi A, Sanjay S. Updates in the man-
agement of diabetic macular edema. J Diabetes Res
2015;2015:794036.
4. Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-
vascular endothelial growth-factor agents and patient moni-
toring in retinal vein occlusion and diabetic macular edema.
Clin Ophthalmol 2014;8:1611–21.
5. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab
for diabetic macular edema: results from 2 phase III ran-
domized trials: RISE and RIDE. Ophthalmology 2012;119:
789–801.
6. Brown DM, Nguyen QD, Marcus DM, et al. Long-term out-
comes of ranibizumab therapy for diabetic macular edema: the
36-month results from two phase III trials: RISE and RIDE.
Ophthalmology 2013;120:2013–22.
7. Browning DJ, Glassman AR, Aiello LP, et al. Relationship
between optical coherence tomography-measured central
retinal thickness and visual acuity in diabetic macular edema.
Ophthalmology 2007;114:525–36.
8. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of
ranibizumab on diabetic retinopathy severity and progression.
Arch Ophthalmol 2012;130:1145–52.
9. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects
of therapy with ranibizumab on diabetic retinopathy severity
and baseline risk factors for worsening retinopathy. Ophthal-
mology 2015;122:367–74.
10. Cheema HR, Al Habash A, Al-Askar E. Improvement of
visual acuity based on optical coherence tomography patterns1350following intravitreal bevacizumab treatment in patients with
diabetic macular edema. Int J Ophthalmol 2014;7:251–5.
11. Rayess N, Rahimy E, Ying GS, et al. Baseline choroidal
thickness as a predictor for response to anti-vascular endo-
thelial growth factor therapy in diabetic macular edema. Am J
Ophthalmol 2015;159:85–91.
12. Mushtaq B, Crosby NJ, Dimopoulos AT, et al. Effect of initial
retinal thickness on outcome of intravitreal bevacizumab
therapy for diabetic macular edema. Clin Ophthalmol 2014;8:
807–12.
13. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial
evaluating ranibizumab plus prompt or deferred laser or
triamcinolone plus prompt laser for diabetic macular edema.
Ophthalmology 2010;117:1064–1077.e35.
14. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The
RESTORE study: ranibizumab monotherapy or combined with
laser versus laser monotherapy for diabetic macular edema.
Ophthalmology 2011;118:615–25.
15. Funatsu H, Noma H, Mimura T, et al. Association of vitreous
inﬂammatory factors with diabetic macular edema. Ophthal-
mology 2009;116:73–9.
16. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibi-
zumab for diabetic macular edema with prompt versus de-
ferred laser treatment: 5-year randomized trial results.
Ophthalmology 2015;122:375–81.
17. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aﬂi-
bercept for diabetic macular edema: 100-week results from the
VISTAandVIVID studies.Ophthalmology 2015;122:2044–52.
18. Wells JA, Glassman AR, Ayala AR, et al. Aﬂibercept, bev-
acizumab, or ranibizumab for diabetic macular edema. N Engl
J Med 2015;372:1193–203.Footnotes and Financial DisclosuresOriginally received: October 22, 2015.
Final revision: January 20, 2016.
Accepted: February 2, 2016.
Available online: March 16, 2016. Manuscript no. 2015-1847.
1 California Retina Consultants, Santa Barbara, California.
2 Genentech, Inc., South San Francisco, California.
Presented in part at: American Academy of Ophthalmology Annual
Meeting, October 2014, Chicago, Illinois; and 38th Macula Society Annual
Meeting, February 2015, Scottsdale, Arizona.
Financial Disclosure(s):
The author(s) have made the following disclosure(s): D.J.P.: Consultant e
Alimera (Alpharetta, GA); Allergan (Irvine, CA); Genentech, Inc., South
San Francisco, California; Santen; ThromboGenics
P.W.: Employee e Genentech, Inc., South San Francisco, California
B.D.: Employee e Genentech, Inc., South San Francisco, California
S.G.: Employee e Genentech, Inc., South San Francisco, California
Genentech, Inc., South San Francisco, California, participated in the design
and conduct of the study; data collection, analysis, and interpretation
of results; and preparation, review, and approval of the manuscript.Third-party writing assistance was provided by Grace H. Lee, PharmD, of
Envision Scientiﬁc Solutions, and funded by Genentech, Inc.
Author Contributions:
Conception and design: Pieramici
Analysis and interpretation: Pieramici, Wang, Ding, Gune
Data collection: none
Obtained funding: none
Overall responsibility: Pieramici, Wang, Ding, Gune
Abbreviations and Acronyms:
BCVA ¼ best-corrected visual acuity; CFT ¼ central foveal thickness;
CRT ¼ central retinal thickness; DME ¼ diabetic macular edema;
DR ¼ diabetic retinopathy; ETDRS ¼ Early Treatment Diabetic Reti-
nopathy Study; OCT ¼ optical coherence tomography; VEGF ¼ vascular
endothelial growth factor.
Correspondence:
Dante J. Pieramici,MD, California Retina Consultants, 515 EastMicheltorena
Street, Suite C, Santa Barbara, CA 93103. E-mail: dpieramici@yahoo.com.
